Advocin (Danofloxacin Mesylate) Sterile Injectable Solution

ADVOCIN a cost effective alternative for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica and Pasteurella multocida. Advocin can quickly reach high concentrations at the site of infection.

• Cost effective treatment when compared to other drugs in the same class means a better bottom line in your herd health budget.
• Short slaughter-withhold, so animals can be treated later in the feeding process without worry about residue.
• Reaches high concentrations in the lungs at the site of infection making it more effective against BRD infections.

Care should be taken to dose accurately. Administered dose volume should not exceed 15 mL per injection site.

• Single-Dose Therapy (BRD Treatment and Control in Cattle at High Risk): Administer subcutaneously at 8 mg/kg of body weight (2 mL/100 lb) as a one-time injection.
• Multi-Day Therapy (BRD Treatment): Administer subcutaneously at 6 mg/kg of body weight (1.5 mL/100 lb) with this treatment repeated once approximately 48 hours following the first injection.

*Administered dose volume sould not exceed 15mL per injection site.

Clinical field studies indicate that ADVOCIN (danofloxacin injection) Sterile Injectable Solution is effective for the control of respiratory disease in beef cattle at high risk of developing BRD. Cattle at high risk of developing typically experience one or more of the following risk factors:

• Commingling from multiple sale barns/sources
• Extended transport times and shrink
• Exposure to wet or cold weather conditions or wide temperature swings
• Stressful arrival processing procedures (such as castration, dehorning, or branding
• Recent weaning or poor vaccination history

Residue Warnings: Animals intended for human consumption must not be slaughtered within 4 days from the last treatment. Do not use in cattle intended for dairy production. A withdrrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

Antibacterial Warnings: Use of antibacterial drugs in the absence of a susceptible bacterial infection is unlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistant bacteria.

HUMAN WARNINGS: For use in animals only. Keep out of reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few excessive expsure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. To report adverse reactions or to obtain a copy of the Material Safety Data Sheet (MSDS), call 1-888-963-8471.

PRECAUTIONS: The effects of danofloxacin on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter. Quinolone-class drugs should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associate with CNS stimulation, which may lead to convulsive seizures. Quinolone-class drugs have been shown to produce erosions of catilage of weight-bearing joints and other signs of arthropathy in immature, rapidly growing animals of various species. Refer to Animal Safety for information specific to danofloxacin.

ADVERSE REACTIONS: A hypersensitivity reaction was noted in 2 healthy calves treated with ADVOCIN in a laboratory study. In one location of a multi-site field trial, one out of the 41 calves treated with 6 mg/kg q 48 hours showed lameness on Day 6 only. In this same field trial location one of 38 calves treated with 8 mg/kg once became lame 4 days after treatment and remained lame on the last day of the study (Day 10). Another calf in the same treatment group developed lameness on the last day of the study.